Évaluation de l’immunotoxicité en recherche et dans le cadre du développement biomédical

Free Access

Issue		Biologie Aujourd’hui Volume 216, Number 3-4, 2022


Page(s)		167 - 181
DOI		https://doi.org/10.1051/jbio/2022020
Published online		6 février 2023

Ai, W., Li, H., Song, N., Li, L., Chen, H. (2013). Optimal method to stimulate cytokine production and its use in immunotoxicity assessment. Int J Environ Res Public Health, 10, 3834–3842. [CrossRef] [PubMed] [Google Scholar]
American College of Toxicology. (2020). Fundamental approaches to immunotoxicity assessment in preclinical safety studies. https://interact.actox.org/viewdocument/fundamental-approaches-to-immunotox. [Google Scholar]
Anderson, S.E., Shane, H.L. (2018). Investigative immunotoxicology. Methods Mol Biol, 1803, 27–46. [CrossRef] [PubMed] [Google Scholar]
Auguste, M., Melillo, D., Corteggio, A., Marino, R., Canesi, L., Pinsino, A., Italiani, P., Boraschi, D. (2022). Methodological approaches to assess innate immunity and innate memory in marine invertebrates and humans. Front Toxicol, 4, 842469. [CrossRef] [PubMed] [Google Scholar]
Bannish, G. (2018). The importance of immunopharmacology in non-clinical safety assessment of immune-oncology biotherapeutics. https://www.toxicology.org/groups/rc/NorCal/docs/20180501-presentation-greg-bannish-v2.pdf. [Google Scholar]
Boisseau, C., Perrot, S. (2012). Évaluation de l’immunotoxicité d’une molécule pharmaceutique (chimique ou biologique) en développement : Bilan des tests disponibles et proposition d’un arbre de décisions pour l’identification des dangers et l’évaluation du risque immunotoxique, École vétérinaire de Maisons-Alfort, Maisons-Alfort, pp. 1-206. [Google Scholar]
Bouchez, C., Gervais, F., Fleurance, R., Palate, B., Legrand, J.-J., Descotes, J. (2012). Development of a Delayed-Type Hypersensitivity (DTH) model in the Cynomolgus monkey. J Toxicol Pathol, 25, 183-188. [CrossRef] [PubMed] [Google Scholar]
Boverhof, D.R., Ladics, G., Luebke, B., Botham, J., Corsini, E., Evans, E., Germolec, D., Holsapple, M., Loveless, S.E., Lu, H., van der Laan, J.W., White, K.L., Yang, Y. (2014). Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: A workshop summary. Regul Toxicol Pharmacol, 68, 96-107. [CrossRef] [PubMed] [Google Scholar]
Burleson, G.R., Burleson, F.G. (2008). Testing human biologicals in animal host resistance models. J Immunotoxicol, 5, 23-31. [CrossRef] [PubMed] [Google Scholar]
Burleson, S.C.M., Freebern, W.J., Burleson, F.G., Burleson, G.R., Johnson, V.J., Luebke, R.W. (2018). Host resistance assays. Methods Mol Biol, 1803, 117-145. [CrossRef] [PubMed] [Google Scholar]
Burns-Naas, L., Pallardy, M. (2013). Immunotoxicology, in: Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations, John Wiley & Sons, Ltd., New Jersey, pp. 313-346. [CrossRef] [Google Scholar]
Chen, H.-C. (2005). Boyden chamber assay. Methods Mol Biol, 294, 15-22. [PubMed] [Google Scholar]
Corsini, E., Loveren, H.V. (2014). Molecular immunotoxicology (1st ed.), Wiley-VCH, Weinheim, pp. 1-329. [Google Scholar]
De Jong, W.H., Van Loveren, H. (2007). Screening of xenobiotics for direct immunotoxicity in an animal study. Methods, 41, 3-8. [CrossRef] [PubMed] [Google Scholar]
Dean, J.H. (2004). A brief history of immunotoxicology and a review of the pharmaceutical guidelines. Int J Toxicol, 23, 83-90. [CrossRef] [PubMed] [Google Scholar]
Dean, J.H., Padarathsingh, M.L., Jerrells, T.R. (1979). Assessment of immunobiological effects induced by chemicals, drugs or food additives. I. Tier testing and screening approach. Drug Chem Toxicol, 2, 5-17. [CrossRef] [PubMed] [Google Scholar]
Dean, J.H., Hincks, J.R., Remandet, B. (1998). Immunotoxicology assessment in the pharmaceutical industry. Toxicol Lett, 102-103, 247-255. [CrossRef] [PubMed] [Google Scholar]
Descotes, J. (2009). Immunotoxicity of monoclonal antibodies. MAbs, 1(2), 104-111. [CrossRef] [PubMed] [Google Scholar]
Descotes, J. (2012). Safety immunopharmacology: Evaluation of the adverse potential of pharmaceuticals on the immune system. J Pharmacol Toxicol Methods, 66, 79-83. [CrossRef] [PubMed] [Google Scholar]
Descotes, J. (2014). Immune system, in: P. Wexler (Ed.), Encyclopedia of toxicology (3rd ed.), Academic Press, pp. 1004-1023. [CrossRef] [Google Scholar]
Dintzis, R.Z., Vogelstein, B., Dintzis, H.M. (1982). Specific cellular stimulation in the primary immune response: Experimental test of a quantized model. Proc Natl Acad Sci USA, 79, 884-888. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
Dobrovolskaia, M.A., McNeil, S.E. (2013). Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release, 172, 456-466. [CrossRef] [PubMed] [Google Scholar]
Elmore, S.A. (2012). Enhanced histopathology of the immune system: A review and update. Toxicol Pathol, 40, 148-156. [CrossRef] [PubMed] [Google Scholar]
EMA. (2018a). ICH S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. https://www.ema.europa.eu/en/ich-s6-r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals. [Google Scholar]
EMA. (2018b). ICH S8 Immunotoxicity studies for human pharmaceuticals. https://www.ema.europa.eu/en/ich-s8-immunotoxicity-studies-human-pharmaceuticals. [Google Scholar]
Espenschied, S.T., Tighe, R.M., Gowdy, K.M. (2018). Flow cytometry for the immunotoxicologist. Methods Mol Biol, 1803, 183-197. [CrossRef] [PubMed] [Google Scholar]
Farmer, J.T., Dietert, R.R. (2013). Chapter 10 – Immunotoxicology assessment in drug development, in: A.S. Faqi (Ed.), A comprehensive guide to toxicology in nonclinical drug development (2nd ed.), Academic Press, pp. 247-262. [CrossRef] [Google Scholar]
Galbiati, V., Mitjans, M., Corsini, E. (2010). Present and future of in vitro immunotoxicology in drug development. J Immunotoxicol, 7, 255-267. [CrossRef] [PubMed] [Google Scholar]
Germolec, D., Luebke, R., Rooney, A., Shipkowski, K., Vandebriel, R., van Loveren, H. (2017). Immunotoxicology: A brief history, current status and strategies for future immunotoxicity assessment. Curr Opin Toxicol, 5, 55-59. [CrossRef] [PubMed] [Google Scholar]
Germolec, D.R., Shipkowski, K.A., Frawley, R.P., Evans, E. (2018). Markers of inflammation. Methods Mol Biol, 1803, 57-79. [CrossRef] [PubMed] [Google Scholar]
Geyer, H., Wuhrer, M., Resemann, A., Geyer, R. (2005). Identification and characterization of keyhole limpet hemocyanin N-glycans mediating cross-reactivity with Schistosoma mansoni. J Biol Chem, 280, 40731-40748. [CrossRef] [PubMed] [Google Scholar]
Grant, C.F., Lefevre, E.A., Carr, B.V., Prentice, H., Gubbins, S., Pollard, A.J., Charreyre, C., Charleston, B. (2012). Assessment of T-dependent and T-independent immune responses in cattle using a B cell ELISPOT assay. Vet Res, 43, 68. [CrossRef] [PubMed] [Google Scholar]
Grimaldi, C., Finco, D., Fort, M.M., Gliddon, D., Harper, K., Helms, W.S., Mitchell, J.A., O’Lone, R., Parish, S.T., Piche, M.-S., Reed, D.M., Reichmann, G., Ryan, P.C., Stebbings, R., Walker, M. (2016). Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine, 85, 101-108. [CrossRef] [PubMed] [Google Scholar]
Haggerty, H.G. (2007). Immunotoxicity testing in non-rodent species. J Immunotoxicol, 4, 165-169. [CrossRef] [PubMed] [Google Scholar]
Hartung, T., Corsini, E. (2013). Immunotoxicology: Challenges in the 21st century and in vitro opportunities. ALTEX, 30, 411-426. [CrossRef] [PubMed] [Google Scholar]
Janeway, C.J., Travers, P., Walport, M., Shlomchik, M.J. (2001). B-cell activation by armed helper T cells, in: Immunobiology: The immune system in health and disease (5th ed.), Garland Science, New York, pp. 402-426. [Google Scholar]
Karmaus, P.W.F., Karmaus, A.L. (2018). Challenges for integrating immunotoxicology into the twenty-first-century toxicology testing paradigm. Methods Mol Biol, 1803, 385-396. [CrossRef] [PubMed] [Google Scholar]
Kaul, R. (2013). Chapter 917 – Hepatitis, in: The immunoassay handbook (4th ed.), Elsevier, Amsterdam, pp. 901-911. [Google Scholar]
Kawabata, T.T., Evans, E.W. (2012). Development of immunotoxicity testing strategies for immunomodulatory drugs. Toxicol Pathol, 40, 288-293. [Google Scholar]
Kawai, R., Ito, S., Aida, T., Hattori, H., Kimura, T., Furukawa, T., Mori, K., Sanbuissho, A., Kawada, T. (2013). Evaluation of primary and secondary responses to a T-cell-dependent antigen, keyhole limpet hemocyanin, in rats. J Immunotoxicol, 10, 40-48. [CrossRef] [PubMed] [Google Scholar]
Koller, L.D. (2001). A perspective on the progression of immunotoxicology. Toxicology, 160, 105-110. [CrossRef] [PubMed] [Google Scholar]
Kuper, C.F., van Bilsen, J., Cnossen, H., Houben, G., Garthoff, J., Wolterbeek, A. (2016). Development of immune organs and functioning in humans and test animals: Implications for immune intervention studies. Reprod Toxicol, 64, 180-190. [CrossRef] [PubMed] [Google Scholar]
Ladics, G.S. (2018). The sheep erythrocyte T-Dependent Antibody Response (TDAR). Methods Mol Biol, 1803, 83-94. [CrossRef] [PubMed] [Google Scholar]
Lebrec, H., Cowan, L., Lagrou, M., Krejsa, C., Neradilek, M.B., Polissar, N.L., Black, L., Bussière, J. (2011). An inter-laboratory retrospective analysis of immunotoxicological endpoints in non-human primates: T-cell-dependent antibody responses. J Immunotoxicol, 8, 238-250. [CrossRef] [PubMed] [Google Scholar]
Lebrec, H., Molinier, B., Boverhof, D., Collinge, M., Freebern, W., Henson, K., Mytych, D.T., Ochs, H.D., Wange, R., Yang, Y., Zhou, L., Arrington, J., Christin-Piché, M.S., Shenton, J. (2014). The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation. Regul Toxicol Pharmacol, 69, 7-21. [CrossRef] [PubMed] [Google Scholar]
Logel, D.Y., Jaschke, P.R. (2020). A high-resolution map of bacteriophage φX174 transcription. Virology, 547, 47-56. [CrossRef] [Google Scholar]
Lorenzo-Herrero, S., Sordo-Bahamonde, C., González, S., López-Soto, A. (2020). Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay. Methods Enzymol, 631, 483-495. [CrossRef] [PubMed] [Google Scholar]
Luster, M.I. (2014). A historical perspective of immunotoxicology. J Immunotoxicol, 11, 197-202. [CrossRef] [PubMed] [Google Scholar]
Mahalingam, S., Peter, J., Xu, Z., Bordoloi, D., Ho, M., Kalyanaraman, V.S., Srinivasan, A., Muthumani, K. (2021). Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. Heliyon, 7, e06836. [CrossRef] [PubMed] [Google Scholar]
Martin, P.L. (2010). Chapter 17 – Reproductive toxicity testing for biopharmaceuticals, in: Preclinical safety evaluation of biopharmaceuticals, John Wiley& Sons Ltd., New Jersey, pp. 1-21. [Google Scholar]
Meunier, S., de Bourayne, M., Hamze, M., Azam, A., Correia, E., Menier, C., Maillère, B. (2020). Specificity of the T cell response to protein biopharmaceuticals. Front Immunol, 11, 1550. [CrossRef] [PubMed] [Google Scholar]
Mond, J.J., Vos, Q., Lees, A., Snapper, C.M. (1995). T cell independent antigens. Curr Opin Immunol, 7, 349-354. [CrossRef] [PubMed] [Google Scholar]
Nagarkatti, M., Rieder, S.A., Nagarkatti, P.S. (2018). Evaluation of cell proliferation and apoptosis in immunotoxicity testing. Methods Mol Biol, 1803, 209-230. [CrossRef] [PubMed] [Google Scholar]
OECD. (1998). Test No. 409: Repeated dose 90-day oral toxicity study in non-rodents. https://www.oecd-ilibrary.org/environment/test-no-409-repeated-dose-90-day-oral-toxicity-study-in-non-rodents_9789264070721-en. [CrossRef] [Google Scholar]
OECD. (2008). Test No. 407: Repeated dose 28-day oral toxicity study in rodents. https://www.oecd-ilibrary.org/environment/test-no-407-repeated-dose-28-day-oral-toxicity-study-in-rodents_9789264070684-en. [CrossRef] [Google Scholar]
OECD. (2018). Test No. 443: Extended one-generation reproductive toxicity study. https://www.oecd-ilibrary.org/fr/environment/test-no-443-extended-one-generation-reproductive-toxicity-study_9789264185371-en. [CrossRef] [Google Scholar]
OECD. (2022). Test No. 406: Skin sensitisation. https://www.oecd-ilibrary.org/fr/environment/test-no-406-skin-sensitisation_9789264070660-en. [Google Scholar]
Oellerich, M., Brandhorst, G., Shipkova, M., Wieland, E. (2012). Chapter 16 – Biomarkers: The link between therapeutic drug monitoring and pharmacodynamics of immunosuppressants, in: A. Dasgupta (Ed.), Therapeutic drug monitoring, Academic Press, pp. 349-372. [CrossRef] [PubMed] [Google Scholar]
Orange, J.S., Ballow, M., Stiehm, E.R., Ballas, Z.K., Chinen, J., De La Morena, M., Kumararatne, D., Harville, T.O., Hesterberg, P., Koleilat, M., McGhee, S., Perez, E.E., Raasch, J., Scherzer, R., Schroeder, H., Seroogy, C., Huissoon, A., Sorensen, R.U., Katial, R. (2012). Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol, 130, S1-S24. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
Peachee, V.L., Smith, M.J., Beck, M.J., Stump, D.G., White, K.L. (2014). Characterization of the T-dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) in the Göttingen minipig. J Immunotoxicol, 11, 376-382. [CrossRef] [PubMed] [Google Scholar]
Peyton Myers, L. (2018). Clinical immunotoxicology. Methods Mol Biol, 1803, 15-26. [CrossRef] [PubMed] [Google Scholar]
Plitnick, L.M., Herzyk, D.J. (2010). The T-dependent antibody response to keyhole limpet hemocyanin in rodents. Methods Mol Biol, 598, 159-171. [CrossRef] [PubMed] [Google Scholar]
Plunkett, L.M., Kaplan, A.M., Becker, R.A. (2010). An enhanced tiered toxicity testing framework with triggers for assessing hazards and risks of commodity chemicals. Regul Toxicol Pharmacol, 58, 382-394. [CrossRef] [PubMed] [Google Scholar]
Potter, T.M., Neun, B.W., Dobrovolskaia, M.A. (2018). In vitro and in vivo methods for analysis of nanoparticle potential to induce delayed-type hypersensitivity reactions. Methods Mol Biol, 1682, 197-210. [CrossRef] [PubMed] [Google Scholar]
Rabadi, T., Brady, M.F. (2022). Tetanus toxoid. http://www.ncbi.nlm.nih.gov/books/NBK557415/. [Google Scholar]
Richards, L., Erko, B., Ponpetch, K., Ryan, S.J., Liang, S. (2019). Assessing the nonhuman primate reservoir of Schistosoma mansoni in Africa: A systematic review. Infect Dis Poverty, 8, 32. [CrossRef] [PubMed] [Google Scholar]
Rumianek, A.N., Greaves, D.R. (2020). How have leukocyte in vitro chemotaxis assays shaped our ideas about macrophage migration? Biology, 9, E439. [CrossRef] [PubMed] [Google Scholar]
ScienceDirect. (2017). Hepatitis B surface antigen – An overview. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hepatitis-b-surface-antigen. [Google Scholar]
Sharon, R., McMaster, P.R., Kask, A.M., Owens, J.D., Paul, W.E. (1975). DNP-Lys-ficoll: A T-independent antigen which elicits both IgM and IgG anti-DNP antibody-secreting cells. J Immunol, 114, 1585-1589. [CrossRef] [PubMed] [Google Scholar]
Taylor, L., Recio, C., Greaves, D.R., Iqbal, A.J. (2018). In vitro migration assays. Methods Mol Biol, 1784, 197-214. [CrossRef] [PubMed] [Google Scholar]
The European Commission. (2018). Commission Regulation (EU) 2018/1881. https://eur-lex.europa.eu/eli/reg/2006/1907. [Google Scholar]
Thériaque. (2021a). Monographie DEXAMETHASONE MYL 4MG/1ML SOL INJ. https://www.theriaque.org/apps/monographie/index.php?id=14274&type=SP&popup=1&imprimer=1&info%5B%5D=COMPO&info%5B%5D=CLASS&info%5B%5D=GENE&info%5B%5D=CHOIX&info%5B%5D=ADMIN&info%5B%5D=CONSV&info%5B%5D=INDIC&info%5B%5D=NON_INDIC&info%5B%5D=POSO&info%5B%5D=C_INDIC&info%5B%5D=PREC_EMP&info%5B%5D=N_C_INDIC&info%5B%5D=INTER&info%5B%5D=GROSSESSE&info%5B%5D=CONDUITE&info%5B%5D=EFFET. [Google Scholar]
Thériaque. (2021b). Monographie ENDOXAN 1000MG PDR INJ. https://www.theriaque.org/apps/monographie/index.php?id=8878&type=SP&popup=1&imprimer=1&info%5B%5D=COMPO&info%5B%5D=CLASS&info%5B%5D=GENE&info%5B%5D=CHOIX&info%5B%5D=ADMIN&info%5B%5D=CONSV&info%5B%5D=INDIC&info%5B%5D=NON_INDIC&info%5B%5D=POSO&info%5B%5D=C_INDIC&info%5B%5D=PREC_EMP&info%5B%5D=N_C_INDIC&info%5B%5D=INTER&info%5B%5D=GROSSESSE&info%5B%5D=CONDUITE&info%5B%5D=EFFET. [Google Scholar]
Thériaque. (2021c). Monographie SANDIMMUN 50MG/ML SOL INJ AMP 1ML. https://www.theriaque.org/apps/monographie/index.php?id=4073&type=SP&popup=1&imprimer=1&info%5B%5D=COMPO&info%5B%5D=CLASS&info%5B%5D=GENE&info%5B%5D=CHOIX&info%5B%5D=ADMIN&info%5B%5D=CONSV&info%5B%5D=INDIC&info%5B%5D=NON_INDIC&info%5B%5D=POSO&info%5B%5D=C_INDIC&info%5B%5D=PREC_EMP&info%5B%5D=N_C_INDIC&info%5B%5D=INTER&info%5B%5D=GROSSESSE&info%5B%5D=CONDUITE&info%5B%5D=EFFET. [Google Scholar]
US EPA. (1996a). Biochemicals test guidelines: OPPTS 880.3550 immunotoxicity. https://www.regulations.gov/document/EPA-HQ-OPPT-2009-0158-0005. [Google Scholar]
US EPA. (1996b). Biochemicals test guidelines: OPPTS 880.3800 immune response. https://www.regulations.gov/document/EPA-HQ-OPPT-2009-0158-0006. [Google Scholar]
US EPA. (1996c). Health effects test guidelines: OPPTS 870.7800 immunotoxicity. https://www.regulations.gov/document/EPA-HQ-OPPT-2009-0156-0049. [Google Scholar]
Vos, J.G., Moore, J.A. (1977). Immune suppression as related to toxicology. CRC Crit Rev Toxicol, 5, 67-101. [CrossRef] [PubMed] [Google Scholar]
Yao, W., Ding, M., Bao, L., Zhao, Y., Wang, D., Li, Y., Qu, Y., Hao, C. (2020). Human monocyte-derived dendritic cells as an in vitro alternative model cell to evaluate the immunotoxicity of 2, 4-Dinitrochlorobenzene. Toxicol Lett, 330, 118-127. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.